Department of Orthopedic, First People's Hospital of Kashgar Area, No 120 Yingbin Road, Kashgar City, Xinjiang 844000, China.
Department of Micro Reconstruction Surgery, The First Affiliated Hospital of Xinjiang Medical University, No 137 Liyushan Road, Urumqi, Xinjiang 830054, China.
Biosci Rep. 2019 Nov 29;39(11). doi: 10.1042/BSR20170080.
Dysregulation of miRNAs has been shown to contribute to multiple tumorigenic processes, as well as to correlate with tumour progression and prognosis. miR-199a has been shown to be dysregulated in multiple tumour types. However, the association between miR-199a and the chemoresistance features of osteosarcoma are not well understood, the target genes for miR-199a and the regulatory mechanisms are also unknown. In the present study, we demonstrated that miR-199a is expressed at low levels in osteosarcoma cells and patient samples. By the selection and establishment of cisplatin resistant osteosarcoma cell line, we observed a correlation between miR-199a and cisplatin resistance in osteosarcoma cells: resistant cells exhibit attenuated miR-199a expressions and exogenous overexpression of miR-199a sensitizes osteosarcoma cells to cisplatin. Moreover, we identified HIF-1α as a direct target for miR-199a. Intriguingly, cisplatin resistant osteosarcoma cells display significantly elevated HIF-1α expression under hypoxia. We report here overexpression of miR-199a resensitizes cisplatin resistant cells to cisplatin through inhibition of HIF-1α in vitro and in vivo. Finally, by analysing the clinical osteosarcoma patient samples, we demonstrate a reverse correlation between miR-199a and HIF-1α mRNAs. Our study will provide mechanisms for the miRNA-mediated anticancer therapy and miR-199a may be considered a promising therapeutic agent for osteosarcoma patients who fail to respond to conventional chemotherapy.
miRNA 的失调已被证明与多种肿瘤发生过程有关,并与肿瘤的进展和预后相关。miR-199a 在多种肿瘤类型中被证明失调。然而,miR-199a 与骨肉瘤的化疗耐药特征之间的关联尚不清楚,miR-199a 的靶基因和调控机制也不清楚。在本研究中,我们证明 miR-199a 在骨肉瘤细胞和患者样本中的表达水平较低。通过选择和建立顺铂耐药骨肉瘤细胞系,我们观察到 miR-199a 与骨肉瘤细胞中的顺铂耐药之间存在相关性:耐药细胞表现出 miR-199a 表达减弱,外源性过表达 miR-199a 使骨肉瘤细胞对顺铂敏感。此外,我们确定 HIF-1α 是 miR-199a 的直接靶基因。有趣的是,在缺氧条件下,顺铂耐药骨肉瘤细胞显示出明显升高的 HIF-1α 表达。我们在这里报告说,miR-199a 的过表达通过抑制 HIF-1α 在体外和体内使顺铂耐药细胞对顺铂重新敏感。最后,通过分析临床骨肉瘤患者样本,我们证明 miR-199a 与 HIF-1α mRNA 之间存在反向相关性。我们的研究将为 miRNA 介导的抗癌治疗提供机制,并且 miR-199a 可能被认为是对常规化疗反应不佳的骨肉瘤患者有前途的治疗剂。